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Abstract
Introduction: 18-Fluorodeoxyglucose positron emission tomography can detect the pulmonary involvement of
intravascular lymphoma that presents no abnormality in a computed tomography scan.
Case presentation: We report the case of a 61-year-old Japanese man who had pulmonary intravascular
lymphoma and no computed tomography abnormality. We were able to make an antemortem diagnosis of
pulmonary intravascular lymphoma by transbronchial lung biopsy according to 18-fluorodeoxyglucose positron
emission tomography findings. He is free of recurrent disease 24 months after chemotherapy.
Conclusions: To the best of our knowledge, this is the first reported case of a long-term survivor of pulmonary
intravascular lymphoma diagnosed by transbronchial lung biopsy under the guide of 18-fluorodeoxyglucose
positron emission tomography.
Introduction
Intravascular lymphoma (IVL), a rare subtype of extrano-
dal diffuse large B-cell lymphoma, is characterized by
malignant cells that proliferate within small vessels [1].
We recently treated a patient who had pulmonary IVL
and who showed no abnormality in computed tomogra-
phy (CT) scans. Gallium scintigraphy showed slightly
increased opacity in both of his lungs. Conversely, 18-
fluorodeoxyglucose positron emission tomography
(FDG-PET) revealed strongly increased tracer levels in
the lower regions of both lungs. We performed a trans-
bronchial lung biopsy (TBLB) according to the FDG
accumulation and established a histological diagnosis. In
our patient, FDG-PET proved to be more useful in diag-
nosing IVL after other radiological modalities - high-
resolution computed tomography (HRCT) and gallium
scintigraphy - had failed to identify pulmonary lesions.
This is a case of pulmonary IVL diagnosed by TBLB
under the guide of FDG-PET findings.
Case presentation
A 61-year-old Japanese man with a four-month history of
dyspnea was referred to our cardiovascular department
because of unexplained dyspnea. His symptoms included
low-grade fever (37°C to 38°C), night sweats, and pro-
gressive dyspnea on exertion during the preceding
month. A physical examination revealed a loud diastolic
murmur in his right second intercostal space but no
jugular vein distention, respiratory crackles, or leg
edema. Laboratory data indicated pancytopenia, inflam-
mation, and liver dysfunction. An examination of the
blood showed a hemoglobin level of 11.5 g/dL, a hemato-
crit level of 33.2%, a platelet count of 8.3 × 10
4/μL, and a
white blood cell count of 5.4 × 10
3/μL. His serum lactate
dehydrogenase (LDH) level was high (698 IU/L, normal
range: 100 to 225). His alanine transaminase levels were
slightly elevated (aspartate aminotransferase 50 IU/L and
alanine aminotransferase 45 IU/L). His C-reactive protein
level was 3.1 mg/dL, and his erythrocyte sedimentation
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(1563 ng/mL, normal range: 20 to 120).
An echocardiography showed severe aortic regurgita-
tion and a prolapsed aortic valve. A transesophageal
echocardiography revealed two small vegetations. We
initially considered that his symptoms resulted from
congestive heart failure caused by infective endocarditis
and so we began empirical therapy. However, antibiotics
(ceftriaxone 2 g/day and gentamicin 180 mg/day) did
not improve his symptoms or laboratory data after two
weeks of therapy. A blood culture detected no bacteria.
We ordered additional laboratory tests in accordance
with the guidelines for a fever of unknown origin. The
results of serological tests for Epstein-Barr virus, cytome-
galovirus, and mycoplasma were negative. An evaluation
of connective tissue disease was nonspecific and yielded
negative results for rheumatoid factor, anti-nuclear antibo-
dies, anti-DNA antibodies, and C- and P-anti-neutrophil
antibodies. Although high levels (4130 U/mL, normal
range: 124 to 466) of soluble interleukin-2 receptor (sIL-
2R) suggested the presence of lymphoproliferative disor-
ders, a systemic CT scan using intravenous contrast
revealed no lymphadenopathy.
A blood gas analysis showed hypoxemia and respiratory
alkalosis, pH 7.461, arterial oxygen tension (PaO2) of 74.1
Torr, arterial carbon dioxide tension (PaCO2) of 27.7
Torr, and concentration of bicarbonate (HCO3-)o f1 9 . 5
mmol/L under room air. We performed pulmonary func-
tion tests to evaluate the cause of the hypoxemia. Our
patient’s forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1)w e r ew i t h i nn o r m a ll i m i t s .
His total lung capacity was 5.65 L (100% predicted) and
his residual volume was 2.41 L (125% predicted). His diffu-
sion capacity (7.51 mL/minutes per mm Hg) was low (41%
predicted).
Our patient’s respiratory symptoms and decreased diffu-
sion in the pulmonary function test indicated the necessity
for further examination. However, a chest radiogram failed
to demonstrate any pathological findings and an HRCT
scan showed no evidence of structural abnormality in his
lungs (Figure 1). Although a gallium scintigraphy showed
slightly increased opacity in both lungs, it was unclear
which part of his lung we should target for additional eva-
luations. In contrast, FDG-PET demonstrated strong
increased tracer levels in the lower dorsal lung field (Fig-
ure 2). The standardized uptake values in the lung field
were 5.0 at the early phase (60 minutes after injection) and
6.8 at the delayed phase (120 minutes after injection). We
decided to perform TBLB from his right lower lung to
explore the pathological state of his lung.
TBLB materials from his right lower lung revealed a
diffuse atypical lymphocyte infiltration within his alveo-
lar capillary vessels (Figure 3A), and immunohistochem-
ical staining identified the infiltrated cells as CD20
+
Figure 1 High-resolution computed tomography image. No structural abnormality is seen in the lung field by high-resolution computed
tomography.
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+ (data not shown). In conclu-
sion, FDG-PET-guided TBLB established a histological
diagnosis of intravascular lymphoma. Our patient was
treated with R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, and predonisolone) and
achieved complete remission after six cycles (Figure 4).
He remains alive and free of recurrent disease 24
months after chemotherapy (sIL-2R 408 U/mL and LDH
159 IU/L).
Discussion
IVL is an aggressive and systemic disease characterized
by massive proliferation of large tumor cells within the
lumina of small vessels [1]. Primary pulmonary involve-
ment is a very rare condition (approximately 5%) of IVL
[2]. The diagnosis of pulmonary IVL is often difficult
because of nonspecific clinical and radiographic findings,
and several cases have been diagnosed during an
autopsy [3,4].
FDG-PET is a noninvasive, three-dimensional, meta-
bolic imaging technique that provides higher sensitivity
than gallium scintigraphy in common lymphoma [5]. In
several previous reports, TBLB was performed in
patients with pulmonary IVL at an advanced stage (that
is, in patients who had CT abnormalities) [6,7]. But
there are only three cases (including our case) in which
Figure 2 18-Fluorodeoxyglucose positron emission tomography images. Sagittal (A) and axial (B) images are shown. Strong tracer uptake
appears in the dorsal site of the lung. The standardized uptake value in the lung field is 6.8 (120 minutes after injection).
Figure 3 Immunohistochemical staining. Biopsy specimens of the lung: hematoxylin and eosin (A) and immunoperoxidase (B) stain of CD20.
Black arrows show CD20
+ lymphocytic infiltration inside the alveolar capillary, a characteristic finding of intravascular lymphoma.
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the early diagnosis of pulmonary IVL without a CT
abnormality [8,9]. FDG accumulation is seen in other
diffuse lung diseases such as tuberculosis, sarcoidosis,
and interstitial lung diseases [10], but, owing to the rar-
ity of pulmonary IVL, a specific pattern of tracer uptake
in this disease is not well known. In our case, the pul-
monary FDG uptake was diffuse, but strong accumula-
tion was seen in the lower dorsal lung field. This
accumulation pattern might reflect the gravitational
effect in pulmonary circulation because distribution of
pulmonary blood flow is highest in the lower lung field,
“zone 3 of pulmonary circulation” [11]. IVL is a diffuse
lymphoproliferative disease within small vessels; there-
fore, strong FDG accumulation in the lower lung field
may suggest the presence of many tumor cells spreading
hematogenously within pulmonary capillary vessels.
The median overall survival of IVL is 10 months, even
after chemotherapy [12]. However, systemic chemother-
apy at an early stage might improve the long-term prog-
nosis of patients with IVL [13,14]. Our patient is rare in
that he has pulmonary IVL and remains in complete
remission more than 24 months after chemotherapy.
This favorable long-term prognosis may reflect the
advantage of FDG-PET, which can detect early lesions
of pulmonary IVL with no CT abnormality.
Conclusions
To the best of our knowledge, this is the first report of
a long-term (24 months) survivor of pulmonary IVL
diagnosed by TBLB according to FDG-PET findings.
We propose that FDG-PET is a useful guide for TBLB
in the early diagnosis of pulmonary intravascular lym-
phoma, especially in patients who have no CT
abnormality.
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